
A study aimed to evaluate the effectiveness and safety of administering single capsule bismuth quadruple therapy (scBQT) three times a day, instead of the standard four times a day, in patients with Helicobacter pylori infection. The study analyzed data from Spanish adult patients registered in the Asociación Española de Gastroenterología Research Electronic Data Capture (REDCap) database between June 2013 and March 2021. The three-times-a-day scBQT schedule showed significantly better overall cure rates (94%) compared to the four-times-a-day schedule (91%). Adherence and safety were similar for both regimens. Factors like dosage frequency, first-line therapy, PPI dose, and adherence over 90% were associated with infection cure. In conclusion, scBQT three times a day was found to be more effective and equally safe compared to the traditional four times a day schedule.
Like
Save
Share